Positive Results Bring Early Halt to Trial of Dementia Psychosis Drug Nuplazid

San Diego-based Acadia Pharmaceuticals has brought testing of its drug Nuplazid for treating psychosis in people with dementia to an early halt thanks to positive results, reports the San Diego Union Tribune . The drugmaker said it will consult with the U.S. Food and Drug Administration (FDA) next year about approving the drug. The Phase 3 placebo-controlled, double-blind trial assessed whether Nuplazid significantly delayed a relapse to psychosis. "The primary endpoint chosen was not simply a movement on a scale, but an important clinical outcome that physicians and their customers can clearly understand and easily relate to," explained Acadia President Serge Stankovic. The Alzheimer's Association's Maria C. Carrillo said her organization is eager to see the study results. "The need is high because there currently is no FDA-approved treatment for dementia-related psychosis," she noted. "It is especially good to see attention paid to treating the non-cognitive symptoms of Alzheimer's and other dementias."